The first two treatments for idiopathic pulmonary fibrosis will reportedly cost almost $100,000 a year, according to a news report from Bloomberg.

Boehringer Ingelheim’s OFEV (nintedanib), will cost $96,000 per year, while its competitor, Esbriet (pirfenidone) from InterMune/Roche Holding AG, will cost $94,000.

Both therapies recently received approval by the FDA to help treat the disease, which leads to death of 60 to 80% of IPF patients within five years of diagnosis.